Actively Recruiting
Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder
Led by Yale University · Updated on 2026-04-28
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying how the endocannabinoid system functions in people with opioid use disorder (OUD) by measuring the availability of cannabinoid receptor 1 (CB1R) in the brain. This research aims to better understand differences between individuals with OUD and healthy volunteers using advanced brain imaging techniques. The study is a phase 1, interventional trial led by Yale University focusing on brain receptor imaging using a specialized radioligand. Participants will undergo Positron Emission Tomography (PET) scans using a drug called [11C]OMAR to visualize CB1 receptors. Up to 20 mCi of [11C]OMAR will be administered during each PET scan. Study groups include healthy volunteers without significant medical or psychiatric history and individuals diagnosed with opioid use disorder. The study involves screening, MRI, PET scans, and follow-up visits. During the study, participants will have brain imaging and blood tests to assess CB1 receptor availability and serum endocannabinoid levels within four weeks of screening. Researchers will monitor these outcomes to compare between groups. The trial includes no randomization or blinding, and participants will be followed for the duration necessary to complete imaging and assessments. The study is expected to complete by December 2026.
CONDITIONS
Brief Title
OMAR Opioid Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide informed consent
- Male and female 18 years and older
- DSM-5 diagnosis of opioid use disorder (for OUD group)
- Physically healthy with no clinically unstable medical conditions
- Written informed consent and capacity to comply with study procedures
You will not qualify if you...
- Current neuro-psychiatric illness or severe systemic disease (except opioid use disorder in OUD group)
- Presence of ferromagnetic metal in the body or heart pacemaker
- Prior exposure to ionizing radiation exceeding recommended limits when combined with study tracer
- Claustrophobia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 4 weeks of screening
Participants undergo brain imaging using Positron Emission Tomography (PET) with the radioligand [11C]OMAR to characterize cannabinoid receptors.
1 imaging visit (in-person)
Duration - Duration not specified
Participants may complete follow-up visits to monitor outcomes after imaging.
Follow-up visit(s) as needed
Trial Site Locations
Total: 1 location
1
Connecticut Mental Health Center, Clinical Neuroscience Research Unit
New Haven, Connecticut, United States, 06519
Actively Recruiting
Research Team
A
Anahita Bassir Nia, MD
A
Angelina Contreras
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here